Puma Biotechnology has experienced fluctuating financial performance, alternating between periods of narrow net profitability and quarterly net losses as it balances commercialization expenses for its cancer therapies with ongoing research and development investments. Monitoring its quarterly earnings reports, operating cash flow generation, and debt obligations is essential for evaluating its path toward sustained, long-term profitability.